Carmen Kosicek
Psychiatric/Mental Health · Hillsboro, ORNPI 1255863767
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $347,200 of the $538,787 with a category attached, or 64.4%. 27 manufacturers reported payments, led by AbbVie at 39.1% of the total. Reporting peaked in 2022 at $258,317 and has fallen 98.1% since, to $4,931 in 2025. Among psychiatric/mental health clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,322 payments — averaging $407.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$211K
- Teva Pharmaceuticals USA, Inc.$207K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$61K
- USWM, LLC$35K
- Biogen$7K
- Corium, LLC$6K
- plus $13K from 21 others
What the payments were for
- Consulting fees$57,36511%
- Speaking & faculty fees$347,20064%
- Travel & lodging$101,84719%
- Food & beverage$30,5396%
- Education$4220%
- Gifts$1,4140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 572 | $210,557 |
| Teva Pharmaceuticals USA, Inc. | 298 | $206,913 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 141 | $60,502 |
| USWM, LLC | 100 | $34,836 |
| Biogen | 10 | $7,143 |
| Corium, LLC | 38 | $5,790 |
| Alkermes, Inc. | 22 | $3,840 |
| E.r. Squibb & Sons, L.L.C. | 17 | $2,193 |
| Boehringer Ingelheim | 1 | $2,100 |
| Axsome Therapeutics, Inc. | 40 | $1,343 |
| Tris Pharma Inc | 17 | $667 |
| Johnson & Johnson | 12 | $570 |
| Eisai Inc. | 5 | $552 |
| Sunovion Pharmaceuticals Inc. | 6 | $442 |
| Janssen Scientific Affairs, LLC | 4 | $405 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $193 |
| Neurocrine Biosciences, Inc. | 2 | $135 |
| Sage Therapeutics, LLC | 1 | $109 |
| Idorsia Pharmaceuticals US Inc | 6 | $107 |
| Indivior Inc. | 4 | $91 |
| Avion Pharmaceuticals | 4 | $54 |
| Avanir Pharmaceuticals, Inc. | 4 | $54 |
| Lundbeck LLC | 2 | $49 |
| Orexo US, Inc. | 3 | $46 |
| Almatica Pharma LLC | 3 | $44 |
| Noven Therapeutics, LLC | 2 | $36 |
| Cosette Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$538,787 in reported general payments places this provider in the 95th percentile of 540 psychiatric/mental health providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atomoxetine Hcl | 11 | $313 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $276 |
| Diazepam | 18 | $103 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Hillsboro
- Amber HobergHillsboro$1.9M
- Crystal HigbeHillsboro$5K
- Shannon EatonHillsboro$2K
- Christina FuchsHillsboro$1K
- Tina Matthews-HayesPortland$787K
- Johnni CanslerPortland$529K
- Jill CarterPortland$416K
- William BettsEugene$41K
- Michelle VoegelsPortland$29K
- Rance SmithKlamath Falls$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.